Products
Comprehensive catalog of pharmaceutical solutions. Browse categories and send inquiries directly.
| Molecule | Drug Class / Mechanism | Oncology Type | Inquiry | |
|---|---|---|---|---|
Aflibercept |
Anti-VEGF / VEGFR Agent | Solid Tumour | ||
|
Molecule
Aflibercept
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-VEGF / VEGFR Agent |
||||
Ziv-Aflibercept |
Anti-VEGF / VEGFR Agent | Solid Tumour | ||
|
Molecule
Ziv-Aflibercept
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-VEGF / VEGFR Agent |
||||
Brolucizumab (Onc Adjacent) |
Anti-VEGF / VEGFR Agent | Solid Tumour | ||
|
Molecule
Brolucizumab (Onc Adjacent)
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-VEGF / VEGFR Agent |
||||
Cetuximab |
Anti-EGFR mAb | Solid Tumour | ||
|
Molecule
Cetuximab
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-EGFR mAb |
||||
Panitumumab |
Anti-EGFR mAb | Solid Tumour | ||
|
Molecule
Panitumumab
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-EGFR mAb |
||||
Necitumumab |
Anti-EGFR mAb | Solid Tumour | ||
|
Molecule
Necitumumab
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-EGFR mAb |
||||
Nimotuzumab |
Anti-EGFR mAb | Solid Tumour | ||
|
Molecule
Nimotuzumab
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-EGFR mAb |
||||
Matuzumab |
Anti-EGFR mAb | Solid Tumour | ||
|
Molecule
Matuzumab
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-EGFR mAb |
||||
Sacituzumab Govitecan |
ADC | Solid Tumour | ||
|
Molecule
Sacituzumab Govitecan
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
||||
Enfortumab Vedotin |
ADC | Solid Tumour | ||
|
Molecule
Enfortumab Vedotin
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
||||
Tisotumab Vedotin |
ADC | Solid Tumour | ||
|
Molecule
Tisotumab Vedotin
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
||||
Mirvetuximab Soravtansine |
ADC | Solid Tumour | ||
|
Molecule
Mirvetuximab Soravtansine
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
||||
AfliberceptTargeted Therapy (Antibody) |
|
|
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-VEGF / VEGFR Agent |
|
Ziv-AfliberceptTargeted Therapy (Antibody) |
|
|
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-VEGF / VEGFR Agent |
|
Brolucizumab (Onc Adjacent)Targeted Therapy (Antibody) |
|
|
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-VEGF / VEGFR Agent |
|
CetuximabTargeted Therapy (Antibody) |
|
|
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-EGFR mAb |
|
PanitumumabTargeted Therapy (Antibody) |
|
|
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-EGFR mAb |
|
NecitumumabTargeted Therapy (Antibody) |
|
|
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-EGFR mAb |
|
NimotuzumabTargeted Therapy (Antibody) |
|
|
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-EGFR mAb |
|
MatuzumabTargeted Therapy (Antibody) |
|
|
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-EGFR mAb |
|
Sacituzumab GovitecanTargeted Therapy (Antibody-Drug Conjugate) |
|
|
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
|
Enfortumab VedotinTargeted Therapy (Antibody-Drug Conjugate) |
|
|
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
|
Tisotumab VedotinTargeted Therapy (Antibody-Drug Conjugate) |
|
|
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
|
Mirvetuximab SoravtansineTargeted Therapy (Antibody-Drug Conjugate) |
|
|
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
|